Resources
Search all resources on this page or select a tab to see publications, videos, audio, collections of related resources and more.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Information for patients
Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Life Saving Drugs Program resources – Perinatal- and infantile-onset hypophosphatasia (HPP)
A collection of resources for health professionals to help people with perinatal- and infantile-onset hypophosphatasia (HPP) access asfotase alfa (Strensiq®) under the Life Saving Drugs Program.
Life Saving Drugs Program – Perinatal- and infantile-onset hypophosphatasia (HPP) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Perinatal- and infantile-onset hypophosphatasia (HPP) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.
Life Saving Drugs Program – Perinatal- and infantile-onset hypophosphatasia (HPP) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.
Life Saving Drugs Program – Perinatal- and infantile-onset hypophosphatasia (HPP) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.
Life Saving Drugs Program (LSDP) – Medicines reviews recommendations
This document outlines 51 recommendations from the Life Saving Drugs (LSDP) expert panel review.
Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria
A collection of resources for health professionals to help people with paroxysmal nocturnal haemoglobinuria access eculizumab (Soliris®) under the Life Saving Drugs Program.
Fact sheet for patients – New arrangements for eculizumab (Soliris®) for treatment of paroxysmal nocturnal haemoglobinuria
This fact sheet explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuriaFact sheet for prescribers – New arrangements for eculizumab (Soliris®)
This fact sheet for prescribers explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022. It outlines what prescribers need to do to transition their patients to the new arrangements.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuriaLife Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
Life Saving Drugs Program – Gaucher disease (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Gaucher diseaseLife Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Part of a collection: Life Saving Drugs Program resources – Fabry diseaseLife Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.
Part of a collection: Life Saving Drugs Program resources – Pompe diseaseLife Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for paroxysmal nocturnal haemoglobinuria.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuriaLife Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).
Part of a collection: Life Saving Drugs Program resources – Hereditary tyrosinaemia type 1Life Saving Drugs Program – Batten disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.
Part of a collection: Life Saving Drugs Program resources – Batten diseaseLife Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.
Part of a collection: Life Saving Drugs Program resources – Gaucher diseaseLife Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)